Home
About CCRF
RUN/WALK 2012
Events
Friends Nationwide
Natl. Med. Advisory Board
Research Grants
General Donations
                                             

     
Children's Cancer Research FUND
Families and Friends Who care


   


Click Here to Download
Children's Cancer Research Fund's 2011 Grant Application



In the twenty years of funding, CCRF has just awarded its 72nd research grant!  Since 
Children's Cancer Research Fund is not the arm of any one hospital, it is able
 to fund research on a national level.


2011


REDELL, MICHELE, M.D., Ph.D.
Texas Children's Cancer and Hematology Centers
Houston, Texas
*Identifying Chemotherapy Resistance Mechanisms in Relapsed Acute Myeloid Leukemia

SEPE, DANA, M.D.
Center for Childhood Cancer Research & Division of Oncology, The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
*Pharmacokinetics in Pediatric Cancer Patients

DRISSI, RACHID, Ph.D.
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio
*Biology Studies in the First Phase I Trial of a Telomerase Inhibitor in Children with Refractory of Recurrent Solid Tumors and Lyphomas


2010


BARBIERI, EVELINE, M.D., Ph.D.
  Baylor College of Medicine
  Houston, Texas
  *Sestrins Modulate p53-Dependent Responses to Chemotherapy in Neuroblastoma.

KRIVTSOV, ANDREI, Ph.D.
 
Childrens Hospital Boston
  Boston, Massachusetts
  *Preclinical Assessment of Ctnnb1 Suppression for Treatment of MLL-AF9 AML/LSC.

ROY, UPAL BASU, Ph.D., M.P.H.
  New York University Medical Center
  New York, New York
  *Targeting Sox2-positive Stem Cells in Osteosarcoma.

STAKE, NORIKO, M.D.
 
University of California, Davis
  Sacramento, California
  *Leukemia-Specific Ligands Against Childhood Acute Lymphoblastic Leukemia.

2009

ARA, TASNIM, M.D., Ph.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  *Role of IL-6/STAT-3 and AKT signaling in Neuroblastoma Chemoresistance and Tumor
    progression in Bone Marrow Microenvironment.

RAINUSSO, NINO, M.D.
  Baylor College of Medicine
  Houston, Texas
  *Immunotherapy to Target Cancer Stem Cells in Pediatric Osteosarcoma.

SATWANI, PRAKASH, M.D.
  Columbia University
  New York, New York
 
*A Novel Chemotherapy (Romidepsin) and Immunotherapy (Natural Killer Cell) Based Approach
    in Pediatric Leukemia and Lymphomas: Potential for Targeted Adoptive Cellular Immunotherapy (ACI).

VROOMAN, LYNDA, M.D.
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  *Volumetric Bone Mineral Density Changes During and After Childhood Acute Lymphoblastic
    Leukemia Therapy.


2008


KESHELAVA, NINO, M.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  *Overcoming Neuroblastoma Drug Resistance with Histone Deacetylase Inhibitors and Flavopiridol.

MITTLEMAN, STEPHEN D., M.D., Ph.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  *Exploring How Obesity and Adipocytes Affect Childhood Cancer.

OKCU, MEHMET F., M.D., Ph.D.
  Baylor College of Medicine, Texas Childrens Hospital
  Houston, Texas 
  *Glutathione S-Transferase P1 Variation and Survival in Children with High Risk Neuroblastoma.

SONG, HAE-RI, M.D.
  Childrens Hospital Los Angeles
  Los Angeles, California

  *Nuclear Factor I A gene, and Astrocytic Lineage Gene, in Glioma Formation.

2007


ASGHARZADEH, SHAHAB, M.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
 
*Genomics of Metastatic Neuroblastomas Lacking MYCN Amplification.

GREGORY, MARK A., Ph.D.
  University of Colorado Health Sciences Center
  Aurora, Colorado
  *
Identifying Candidates for Targeted Therapy in Combination with FLT3 Inhibition for the Treatment of
    Acute Myeloid Leukemia
.

WELLS, JAMES, M.D.
  Bringham and Women's Hospital, Inc.
  Boston, Massachusetts
  *
EWS-Flil as an Immuno-Therapeutic Target for Ewing's Sarcoma.

2006

ARMSTRONG, MICHAEL B., M.D., PH.D.
  University of Michigan Comprehensive Cancer Center
  Ann Arbor, Michigan
 
*Impact of N-myc on Chemoresistance in Neuroblastoma.

HELLER, KEVIN N., M.D.
  The Rockefeller University
  New York, New York
  *
Epstein-Barr Virus Immunity and Lymphoma.

KEATING, AMY K., M.D.
  UCHSC at Fitzsimmons, Pediatrics
  Aurora, Colorado
  *
Mer Receptor Tyrosine Kinase as a Biological Marker and Therapeutic Target for Pediatric Leukemia.

RABIN, KAREN, M.D.
  Texas Children’s Cancer Center
  Houston, Texas
  *
Acute Lymphoblastic Leukemia in Down Syndrome: An Investigation of Molecular Genetics 
    and Host Toxicity
.

2005

BARRY, ELLY FALZARANO, M.D.
  Dana Farber Cancer Institute
  Boston, Massachusetts
  *Pharmacogenomics of Doxorubicin-induced Cardiotoxicity.

KEATES-BALEEIRO, JENNIFER, M.D.
  Vanderbilt Children's Hospital
  Nashville, Tennessee
  *Testing Novel Therapeutics in a Mouse Model if Inv (16).

ZACHAROULIS, STERGIOS, M.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  *Preclinical Evaluation of VEGFR2/EGFR Inhibition in Combination with MetronomicTemozolomide
    in a Mouse Model of High Grade Gliomas.


2004

HAINING, W. NICHOLAS, B.M., B.CH.
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  *Targeting telomerase as a cancer antigen: a phase 1 pediatric tumor
    vaccine trial.

KARAJANNIS, MATTHIAS, A., M.D.
  Memorial Sloan-Kettering Cancer Center
  New York, New York
  *Role of pro-angiogenic factors in leukemia-stroma interactions.

ONEL, KENAN, M.D., PH.D.
  The University of Chicago
  Chicago, Illinois
  *The Identification of Novel Biomarkers and Therapeutic Targets in
    Pediatric ALL by Correlative Analysis of Genome Copy Number
    Alterations, mRNA Expression, and Clinical Characteristics.


2003

ASGHARZADEH, SHAHAB, M.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  *Gene Expression Profiles of Metastic Neuroblastomas without MYCN
    Amplification Predict Outcome.

ERDREICH-EPSTEIN, ANAT, M.D., PH.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  *The antiangiogenic effect of alphav-integrin inhibition combined with
    fenretinide in mouse models of human brain tumors.

REID, GREGOR, M.D., PH.D.
  BC Research Institute for Child and Family Health
  Vancouver, British Columbia
  *Development of immune therapy for ETV6-AML1 positive leukemia
    using a novel mouse model.


                                                                                                                                   *as of 2000

2002
APLENE, RICHARD, M.D.
  Children's Hospital of Philadelphia
  Philadelphia, Pennsylvania
  * Genetic Polymnorphisms and Anthracycline Associated
     Cardiac Toxicity.

BROWN, VALERIE I., M.D., PH.D.
  Children's Hospital of Philadelphia
  Philadelphia, Pennsylvania
  * Evaluation of mTOR Inhibitors and the Role of IL-7 Signaling in
     Lymphoid Malignancies.

GRAHAM, DOUGLAS K., M.D., PH.D.
  University of Colorado Cancer Center
  Denver, Colorado
  * Evaluation of role of proto-oncogene c-mer in acute
     lymphocytic leukemia.

PUNAM, MALIK, M.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
 
* In Vivo Effects of Erythropoietin Receptor Signaling in Pediatric
     Tumors.

2001

BATRA, SANDEEP, M.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  * Activity of fenretinide (4-HPR) and 4-HPR plus safingol in
     preventing disease progression against pediatric Ewing's
     Sarcoma (ES) and Primitive neuroectodermal Tumors (PNET)
     cell lines In Vitro and In Vivo.

MALIK, PUNAM, M.D.
 Childrens Hospital Los Angeles
  Los Angeles, California
  *
Role of Erythropoietin and Erythropoietin Receptor in Pediatric 
     Tumors.

ROOD, BRIAN, M.D.
  Children's National Medical Center
  Washington, D.C.
  * Methylation of the O6-methylguanine methyltransferase
     (MGMT) gene promoter as a prognostic factor in pediatric high
     grade glioma and medulloblastoma.

WEIGEL, BRENDA, M.D.
  University of Minnesota Medical School
 
Minneapolis, Minnesota
  * Combination Immunotherapy and Chemotherapy for
     Rhabdomyosarcoma.

2000

MAURER, BARRY J., M.D.,  PH.D.
  Childrens Hospital Los Angeles
  Los Angeles, California
  * Novel Retinoid Combinations with Selective Cytotoxicity for
     Malignant Cells.

WANG, LISA L., M.D.
  Baylor College of Medicine, Texas Children's Cancer Center
  Houston, Texas
  * Molecular Basis and Clinical Spectrum of Rothmund-Thomson
     Syndrome.
  

1999

SAVASAN, SUREYYA, M.D.
  Wayne State University
  Detroit, Michigan
  * In Vitro Drug-Induced Apoptosis as a Measure of Chemo-
     sensitivity in Childhood T-Cell Acute Lymphoblastic Leukemia.

VAN TORNOUT, JAN M., M.D., M.S.
  Childrens Hospital Los Angeles
  Los Angeles, California
  * Evidence for Gene - Environmental Interaction(s) in the
     Etiology of Pediatric Brain Cancer.

SWEETSER, DAVID A., M.D., PH.D.
  Fred Hutchinson Cancer Research Center
  Seattle, Washington
  * The Significance of Loss of Heterozygosity in the Patho-
     genesis and Prognosis of Pediatric de novo AML.

1998
Fu, Cecilia, M.D.
  USC School of Medicine/Childrens Hospital Los Angeles
  Los Angeles, California
 
* Evaluation of Apoptotic Oncoproteins in Blast Cells from 
     Pediatric Patients with Leukemia at Diagnosis and at Relapse.

KESHELAVA, NINO, M.D.
  USC School of Medicine/Childrens Hospital
  Los Angeles, California
  * Resistance to Alkylating Agents in Neuroblastoma.

1997
MALONEY, KELLY, M.D.
   University of Colorado Health Sciences Center
   Denver, Colorado
   * Retrospective Analysis of Prognostic Import of TEL 
      Rearrangements and Hyperdiploidy on Treatment Outcomes 
      for Children with Standard Risks ALL treated with a Single 
      Delayed Intensification.

SHOHET, JASON, M.D.
   University of Texas Southwestern Medical Center
   Dallas, Texas
   * Analysis of Differentially Expressive Genes in Normal and 
      Neoplastic B-Cells.

1996
ORCHARD, PAUL, M.D.
   University of Minnesota
   Minneapolis, Minnesota
   * Expression of anti-CD 19 scFv/zeta Chimeric Gene in Human 
      NK Cells.

ERDREICH-EPSTEIN, ANAT, M.D., PH.D.
   USC School of Medicine/Childrens Hospital Los Angeles
   Los Angeles, California
   * Integrin Alpha-v Beta-3 in Angiogenic Signaling in Pediatric 
      Neural Tumors.

1995
ERDREICH-EPSTEIN, ANAT, M.D., PH.D.
   USC School of Medicine/Childrens Hospital Los Angeles
   Los Angeles, California
   * Integrin Alpha-v Beta-3 in Angiogenic Signaling in Pediatric 
      Neural Tumors.

TAUB, JEFFREY, M.D.
   Children's Hospital of Michigan
   Detroit, Michigan
   * The Molecular Basis of Cytarabine Sensity of Down
      Syndrome Children.

1994
WEST, DANIEL C., M.D.
   Dana-Farber Cancer Institute/Harvard Medical School
   Boston, Massachusetts
   * Testing the feasibility of using the PCR Technique to measure
      the presence of Ewing's Sarcoma or Peripheral Neuraoecto-
      dermal Tumors.

SCHMIDT, MARY LOU, M.D.
   Northwestern University Children's Memorial Hospital
   Chicago, Illinois
   * The Biologic Effects of Down-regulation of N-myc Oncogene 
      Expression in Human Neuroblastoma. (continued study)

1993
HAMRE, MERLIN R., M.D., M.P.H.
   Children's Memorial Institute for Education and Research
   Chicago, Illinois
   * Mechanisms of Resistance to Nucleoside Analogue Inhibitors 
      of S-Adenosyl-L-Homocysteine hydrolase in Murine and 
      Human Neuroblastoma Tumor Cell Lines: Enzymatic and 
      Genetic Determinants.

WHITLOCK, JAMES, A., M.D.
   Vanderbilt University Medical Center
   Nashville, Tennessee
   * Acquired and Constitutional Alterations of p53 in the Devel-
      opment and Progression of Childhood Central Nervous 
      System Tumors.

1992
EMANUEL, PETER D., M.D.
   University of Alabama at Birmingham
   Birmingham, Alabama
   * Mechanisms of Response and Effectiveness of 13-Cis 
      Retinoic Acid in the Treatment of Juvenile Chronic 
      Myelogenous Leukemia.

TOMLINSON, GALE E., M.D., PH.D.
   University of Texas Southwestern Medical Center
   Dallas, Texas
   * A Search for predisposition factors in Breats/Sarcoma Cancer 
      Families.

SCHMIDT, MARY LOU, M.D.
   Northwestern University Children's Memorial Hospital
   Chicago, Illinois
   * The Biologic Effects of Down-regulation of N-myc Oncogene 
      Expression in Human Neuroblastoma.

SHANNON, KEVIN, M.D.
   University of California, San Francisco
   San Francisco, California
   * Mutations of the Neurofibromatosis and Ras Genes in 
      Childhood Myeloproliferative Syndromes.


1991
MOULTON, THOMAS, M.D.
   Columbia University College of Physicians & Surgeons
   New York, New York
  
* The Role of Classic Multidrug Resistance in Pediatric Solid 
      Tumors.

RAUCK, AMANDA M., M.D.
   Children's Hospital
   Columbus, Ohio
   * Urokinase and It's Receptor in Pediatric Cancers - the Tumor
      Biology of Wilms' Tumor and Neuroblastoma, Development 
      and Metastasis.

UMIEL, TEHILA, PH.D.
   Children's Hospital of Los Angeles
   Los Angeles, California
   * Isolation, Molecular Characterization and Induction of Differ-
      entiation of Mixed Lineage (Myeloid/Lymphoid) Precursors
      from Norman and Leukemic Human Bone Marrow.

SCHMIDT, MARY LOU, M.D.
   Northwestern University Children's Memorial Hospital
   Chicago, Illinois
   * Inhibition of N-myc Gene Expression with Antisense N-myc 
      RNA.

HUANG, CHIEN-SHENG, M.D.
   University of California, San Diego
   La Jolla, California
   * Use of Ch14.18 and GM-CSF Neuroblastoma.

VAN TORNOUT, JAN M.A., M.D.
   Children's Hospital of Los Angeles
   Los Angeles, California
   * The Use of Neural Networking in Pediatric Outcome of 
      Childhood Cancer.

TOMLINSON, GAIL E., M.D., PH.D.
   University of Texas Southwestern Medical Center
   Dallas, Texas
   * Constitutional p53 Mutations in Childhood Patients.

1990
SAYLORS, ROBERT L. III, M.D.
   Washington University School of Medicine
   St. Louis, Missouri
   * C-myc Activation in Medulloblastoma.

SMITH, THOMAS J., M.D.
   National Jewish Center for Immunology and Respiratory 
   Medicine
   Denver, Colorado
   * Vbeta Specificity of T-cell Leukemia and other T-cell 
      Lymphoproliferative Disorders.

VILLABLANCA, JUDITH, M.D.
   Children's Hospital of Los Angles
   Los Angeles, California
   * Significance of Cellular Proliferation in Neuroblastoma.

1989
WINICK, NAOMI J., M.D.
   University of Texas Southwestern Medical Center
   Dallas, Texas
   * 6-Mercaptopurine Metabolism in Children with Acute
      Lymphoblastic Leukemia.

GREFFE, BRIAN, M.D.
   The Children's Hospital
   Denver, Colorado
   * Effect of L-Asparaginase on the regulatory coagulation
      proteins and vWF as a mechanism for thrombosis in children 
      with leukemia and lymphoma. 

 

Children's Cancer Research Fund
1554 S. Sepulveda Boulevard, Suite 107
Los Angeles, California  90049
Phone: 310-444-0100 
E-mail: ccrfkids@hotmail.com